Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating

The Cigna Group (NYSE:CI) is one of the best defensive stocks to invest in according to analysts. Cigna shares cracked over 10% on July 31 after the company reported its Q2 2025 quarterly results. Following the results, TD Cowen analyst Charles Rhyee reiterated a Buy rating on Cigna, maintaining a $387 price target. He believes the recent pullback in the shares was overdone and sees current levels as an attractive entry point.

While concerns around performance in the Health Insurance Exchange (HIX) segment weighed on sentiment, Rhyee expects the impact to be limited. He points to strength in other parts of the business, particularly Specialty and Care Services, as well as solid momentum in the company’s Pharmacy Benefit Management (PBM) operations, which should help offset pressures.

Rhyee also noted that management’s Q3 guidance appears cautious, especially considering stepped-up investment in improving patient experience. Still, he remains confident in the company’s earnings outlook, with robust EPS growth projections for 2025 and 2026 supporting his valuation.

The Cigna Group (NYSE:CI) is a health services company that provides medical, pharmacy, behavioural health, dental, and supplemental insurance products.

While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025.

Disclosure: None. This article is originally published at Insider Monkey.